Novo Nordisk A/S Common Stock (NVO)

GLP-1 medications are delivering a $6.5 billion blow to U.S. grocery spending, with weight-loss drugs altering consumer purchasing patterns.

NOVO-NORDISK (NYSE:NVO) offers strong growth, solid profitability, and reasonable valuation, making it an attractive pick for investors seeking affordable growth stocks in the pharmaceutical sector.

Barclays has said that it's hard to predict which firm would be affected the most by pharma tariffs, except for Novo Nordisk.

An update on Sana Biotechnology.

Jamie Dimon warns Europe is falling behind the U.S. economically. Market caps show an even wider gap as U.S. tech giants dominate.

BofA slightly raised Q2 estimates for Eli Lilly ahead of earnings as Zepbound sales improve; long-term forecasts for key drugs remain steady.

While Dow Jones futures edged up by 0.17% at the time of writing, the S&P 500 futures were up 0.15%.

In addition to the submission to the EMA, Novo Nordisk aims to make the higher dose of Wegovy widely available throughout the European Union.

Novo Nordisk seeks EMA approval for 7.2 mg Wegovy dose after trials show 21% weight loss in people with obesity and type 2 diabetes.

WeightWatchers completes reorganization, adds new leadership and unveils a women's health initiative targeting menopause care.

While Eli Lilly has struggled in the past year due to competitive pressures, the statistical winds may finally favor LLY stock.

Hims & Hers faces stock pressure after Novo Nordisk ends Wegovy access, citing compounding violations and marketing concerns.

Popular obesity treatments Wegovy and Zepbound are seeing price reductions, but patients still face significant barriers to sustained access.

Novo Nordisk executives overlooked warnings ahead of Wegovy's launch, leading to supply issues, high costs, and challenges competing with Eli Lilly's Zepbound.

Amazon's latest data center will reportedly require the same amount of electricity as 1 million homes.